Anktiva®: An FDA-Approved Game-Changer for Non-Muscle Invasive Bladder Cancer
The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA, a novel immunotherapy, in combination with Bacillus...
Jon Napitupulu
Azitra Unveils Breakthrough Gene Therapy Findings in Netherton Syndrome
Azitra, a biopharmaceutical company specializing in dermatology therapies, announced promising preclinical data demonstrating the potential of its platform for...
Neurogene’s Revolutionary Gene Therapy for Rett Syndrome: Exciting Data Unlocks Hope
Neurogene’s NGN-401 gene therapy for Rett syndrome has exhibited promising safety results in initial clinical trials. After several months...
Lantern Pharma’s Harmonic™ Trial Expands to Japan and Taiwan
Lantern Pharma has received regulatory approval to expand its Phase 2 clinical trial (HarmonicTM) to evaluate the efficacy of...
EMBLAVEO Granted Marketing Authorization in the EU for Life-Saving Antibacterial for Resistant Infections
The European Commission has approved EMBLAVEO® (aztreonam-avibactam) as a treatment for severe infections caused by Gram-negative bacteria. This includes...
New Trials to Target Antibiotics for Pneumonia and UTIs
Two comprehensive studies have demonstrated the effectiveness of algorithm-driven alerts in optimizing antibiotic selection for hospitalized patients with pneumonia...
Unveiling the Revolutionary ALECENSA: A Game-Changer for ALK+ Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the treatment of patients with ALK-positive non-small...
OPM Obtains €5.6 Million for DEMOCRITE Program’s Clinical Development
Oncodesign Precision Medicine (OPM) has received €5.6 million in funding for the DEMOCRITE project, aimed at demonstrating the efficacy...
Delve Bio Presents Study: mNGS in Neurological Infections
Delve Bio and researchers at the University of California, San Francisco collaborated to showcase the potential of metagenomic next-generation...
Artifa’s Allonk: Unprecedented Lupus Breakthrough
Artiva Biotherapeutics has begun a Phase 1 trial of its AlloNK (AB-101) cell therapy in combination with monoclonal antibodies...